A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of SHR-1918 in Patients With Homozygous Familial Hypercholesterolemia
Latest Information Update: 12 Dec 2024
Price :
$35 *
At a glance
- Drugs SHR-1918 (Primary)
- Indications Hyperlipoproteinaemia type II
- Focus Registrational; Therapeutic Use
- Sponsors Beijing Suncadia Pharmaceuticals
- 12 Dec 2024 New trial record